CalmiGo

Longevity senotherapeutics report: TAmiRNA

Latest articles

The Sheekey Science Show – Aging Clocks

Aging clocks - how to measure biological age. I hope you have some time on you hands as today we will talk all about aging...

Berberine could be longevity’s “best-kept secret”

From tackling senescence to lowering blood sugar, berberine is the supplement with a host of tricks up its sleeves. Berberine is a bioactive compound found...

Over a third of Generation X have multiple health problems

More than one in three British adults are suffering from two or more chronic health conditions in middle age, such as recurrent back problems,...

Forget the arms race – it’s time for a longevity race

Professor Andrew Scott outlines how society needs to change in order to capitalise on multi-trillion dollar longevity dividend. Last week, we brought you the views...

Most read

New NAD+ boosting longevity supplement hits the market

Elevant Prime dietary supplement contains a “high purity” form of NMN that has completed safety and toxicology testing. New York based health and wellness brand...

David Sinclair to co-chair $200 million biotech SPAC

Christian Angermayer's Frontier Acquisition Corp. holds significant longevity interest with David Sinclair and Peter Attia as Co-Chairs of the Board. Frontier Acquisition Corporation, a special...

Tree of Longevity – understanding how supplements work

Pathways? Hallmarks? Biomarkers? Understanding the longevity supplements lingo can help you make better choices for your healthspan. Longevity supplements differ from other 'generic supplements' as...
Seno

Editor's picks

The Sheekey Science Show – Aging Clocks

Aging clocks - how to measure biological age. I hope you have some time on you hands as today we will talk all about aging...

Berberine could be longevity’s “best-kept secret”

From tackling senescence to lowering blood sugar, berberine is the supplement with a host of tricks up its sleeves. Berberine is a bioactive compound found...

Over a third of Generation X have multiple health problems

More than one in three British adults are suffering from two or more chronic health conditions in middle age, such as recurrent back problems,...
CalmiGo

Click the globe for translations.

Biomarkers for more stability in life – TAmiRNA is harnessing the power of microRNAs for the development of innovative diagnostic tools.

Over the coming weeks, we will be bringing you extracts from 7 company profiles from our Longevity Senotherapeutics Report. Each profile includes an assessment of Longevity Potential, Pre-Clinical and Clinical Studies, Technology/platform analysis, Safety and Risks, Target Market and Success Factors.

We also study each company’s IP, team, UVP, product efficacy, competitive advantage, runway and inflection point, and much more. Here’s the lowdown on TAmiRNA.

To view a full size version of TAmiRNA’s profile please click here.

TAmiRNA-Profile
.

TAmiRNA is a Biotech company which was founded in 2013 as a spin-off from the University of Natural Resources and Life Sciences Vienna (BOKU). TAmiRNA conducts research and development of microRNA-based diagnostic tests for several age-associated diseases including senescence-associated diseases (senomiR®), osteoporosis (osteomiR®), cardiovascular disease (thrombomiR®), and liver diseases (hepatomiR®). In addition, TAmiRNA serves as a CRO by providing R&D teams at universities and companies with RNA biomarker solutions for drug safety assessments (toxomiR®), as well as compelling solutions for the analysis of non-coding RNAs in biofluids, single-cells or tissue compartments in any research area. Utilising microRNAs as diagnostic and prognostic biomarkers for senescent burden offers unique opportunities to address many of the issues currently present in the field. This includes (but is not limited to) minimally invasive access to biomarker samples, aiding in resolving senescent cell heterogeneity and high translatability. TAmiRNA’s overall mission is to develop novel diagnostic solutions for unmet clinical needs and to offer high-quality analytical services in compliance with the high standards required by diagnostics development. Through doing this, they hope to prolong the stability, health and quality of life of individuals as they age.

TamiRNA
Matthias Hackl, CEO and Co-founder

At launch, the team (consisting of Matthias Hackl, Regina Grillari, Johannes Grillari and Otto Kanzler) had acquired compelling data in relation to secretory microRNA profiles of senescent cells. “The observation that senescent cells could exert a paracrine effect through release of specific microRNAs into the circulation showed us the huge potential of cell-free microRNAs as biomarkers of senescence, aging and age-related diseases.” Shortly after patenting and publishing the data on cross-talk between senescence-associated microRNAs and bone-formation, TAmiRNA was founded to explore the use of microRNAs as osteoporosis biomarkers (osteomiR®) and subsequently also CVD, liver disease and senescence.

TAmiRNA collaborates with expert biostatisticians, bioinformaticians and epidemiologists in order to identify and validate microRNA biomarkers for diagnosis, prognosis, treatment monitoring and drug development. In this way TAmiRNA uses the full resources and expertise of its team to harness the power of microRNAs to create innovative tools that will drive the longevity field forward. The COVID pandemic has revealed the pervasive role and potential impact that RNA base innovations can have on our health and wellness, particularly in regard to disease prevention. Our world is rapidly changing, as is the rate of scientific and technological progress. In order to rapidly diagnose the diseases associated with an increased death rate, new and improved methods are necessary. MiRNAs have the required properties to constitute such a method. Through developing next generation technologies and talent, TAmiRNA is dedicated to constant growth and improvements in order to maintain its competitive advantage in this field.

TamiRNA

To date, TAmiRNA has completed and patented the development of a transcriptomic landscape of cellular senescence. The company plans to continuously expand its senescence microRNA biomarker panel (through preclinical R&D efforts) with cell-type specific biomarkers based on newly generated data. TAmiRNA recognises that the development of accurate diagnostic and prognostic tests for senescence in humans is one of the major hurdles standing in the way of clinical trial success. Hence, it is focused on continuously engaging in partnerships with companies that are developing and validating their novel senotherapeutics. TAmiRNA recognises high potential for mergers or acquisitions of their development projects in the next 3-7 years.

Access to the report can be found HERE, and check out our other senotherapeutic company profiles HERE.

Images courtesy of TAmiRNA

Comment on this article

Eleanor Garth
Deputy Editor Now a science and medicine journalist, Eleanor worked as a consultant for university spin-out companies and provided research support at Imperial College London and various London hospitals in a former life.
CalmiGo

Most popular

New NAD+ boosting longevity supplement hits the market

Elevant Prime dietary supplement contains a “high purity” form of NMN that has completed safety and toxicology testing. New York based health and wellness brand...

David Sinclair to co-chair $200 million biotech SPAC

Christian Angermayer's Frontier Acquisition Corp. holds significant longevity interest with David Sinclair and Peter Attia as Co-Chairs of the Board. Frontier Acquisition Corporation, a special...

Tree of Longevity – understanding how supplements work

Pathways? Hallmarks? Biomarkers? Understanding the longevity supplements lingo can help you make better choices for your healthspan. Longevity supplements differ from other 'generic supplements' as...

Spermidine: the mind-enhancing supplement

Scientists are finding that a high intake of dietary spermidine could slow down (or reverse) the brain aging process. Memory loss and slower brain function...
Seno

Related articles

A pawsitive take in Alzheimer’s disease modelling

As purr-plexing as it may seem, cats may provide key answers in the study of dementia and Alzheimer’s disease. As we get older, our brain...

Reader Poll: just what does your future look like?

Your future is getting inexorably nearer – but will that be in high-tech comfort in your own home, down the road in a state-of-the-art...

Gerostate passes crowdfunding goal for antiaging drug platform

Longevitytech.fund joins investment round as Buck Institute start-up continues crowdfunding campaign to move antiaging drug candidates into mammalian studies. With around two weeks still remaining...

Scientists reverse age-related memory loss in mice

Scientists have successfully reversed age-related memory loss in mice – discovery could lead to the development of treatments to prevent memory loss in people...

Longevity senotherapeutics report: Insilico Medicine

Insilico – on a mission to accelerate senescence drug discovery and development by continuously inventing and deploying new AI technologies. Over the coming weeks, we...
Seno